5'-modified nucleoside monomers and oligonucleotides comprising the same

By specifically modifying the 5' end of siRNA, the problem of poor in vivo resistance to exonuclease digestion caused by unmodified nucleotides was solved, thereby improving the stability of siRNA and the efficiency of target gene inhibition.

CN122404451APending Publication Date: 2026-07-17RIGERNA THERAPEUTICS (BEIJING) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
RIGERNA THERAPEUTICS (BEIJING) CO LTD
Filing Date
2026-04-23
Publication Date
2026-07-17

Smart Images

  • Figure CN122404451A_ABST
    Figure CN122404451A_ABST
Patent Text Reader

Abstract

本公开提供一种修饰的核苷单体及包含该单体的寡核苷酸，以及其制备方法与应用，属于核酸药物技术领域，所述修饰的核苷单体能提高寡聚核苷酸（尤其是双链寡核苷酸）在体内的稳定性和对靶基因的抑制效率。
Need to check novelty before this filing date? Find Prior Art